Cargando…
Association between Pemafibrate Therapy and Triglyceride to HDL-Cholesterol Ratio
Background: Pemafibrate is a novel selective peroxisome proliferator-activated receptor-α modulator, which was demonstrated to reduce serum triglyceride level with few drug-related adverse events in phase II and III clinical trials. However, its clinical implication in real-world practice remains un...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148088/ https://www.ncbi.nlm.nih.gov/pubmed/35628945 http://dx.doi.org/10.3390/jcm11102820 |